|Bid||6.29 x 900|
|Ask||6.34 x 900|
|Day's Range||6.25 - 6.64|
|52 Week Range||3.16 - 7.50|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2020 - Mar 3, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.60|
PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) congratulates Evofem Biosciences, Inc. ("Evofem") (NASDAQ: EVFM) on its recent achievement of two major regulatory and clinical milestones with its lead product candidate Amphora® (L-lactic acid, citric acid and potassium bitartrate), an investigational multipurpose vaginal pH regulator (MVP-R™) for hormone-free birth control and prevention of chlamydia and gonorrhea.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
Benzinga Pro's Stocks To Watch For Monday Evofem Biosciences (EVFM) - Announced its AMPREVENCE study met the primary and secondary endpoints of “reducing the risk of chlamydia and gonorrhea infection, ...
Evofem Biosciences Inc. reported positive results in a mid-stage trial of a treatment for chlamydia and gonorrhea in women, sending its stock up 27% in premarket trade Monday. The San Diego-based company said a phase 2b study of amphora for preventing the two sexually transmitted diseases met its primary and secondary endpoints of reducing the risk of infection and showed it was safe and well tolerated. "In addition to resubmitting our New Drug Application to the U.S. FDA for Amphora for prevention of pregnancy, we also now have statistically significant evidence that Amphora can prevent acquisition of chlamydia and gonorrhea among women, two bacterial infections that are increasing at an alarming annual rate in the U.S.," Evofem Chief Executive Saundra Pelletier said in a statement. The U.S. Centers for Disease Control and Prevention said rates of infection for Chlamydia trachomatis and Neisseria gonorrhea rose for the fifth straight year in the U.S. with almost in 2018 for the fifth consecutive year in the United States. Nearly 2.4 million cases diagnosed. Gonorrhea is becoming antibiotic resistant, making it harder to treat, according to the CDC. The trial involved 860 women who had had been treated for chlamydia or gonorrhea in the four months prior to enrolling in the study. Evofem shares have gained 46% in 2019, while the S&P 500 has gained 25%.
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical stage biopharmaceutical company, today announced positive top-line results from AMPREVENCE, a Phase 2b clinical trial evaluating the efficacy and safety of its lead product candidate Amphora® for the prevention of urogenital chlamydia and gonorrhea in women. The study met both its primary and secondary endpoints of reducing the risk of chlamydia and gonorrhea infection, respectively, and demonstrated that Amphora was generally safe and well tolerated.
Biotech stocks experienced some momentum last week amid a few clinical readouts. Karuna Therapeutics Inc (NASDAQ: KRTX ), which went public in June, was among the biggest gainers of the week on a positive ...
- San Diego Business Journal Recognizes the City's Top 15 Female Business Leaders - SAN DIEGO , Nov. 14, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Chief Executive ...
SAN DIEGO , Nov. 13, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today that Chief Executive Officer Saundra Pelletier will present ...
13Ds are filed with the Securities and Exchange Commission within 10 days of an entity’s attaining a greater than 5% position in any class of a company’s securities. Impactive Capital disclosed on Nov. 1 that it had purchased 44,744 shares of the audio- and video-content maker and distributor, lifting its stake to 3,700,000 shares. The purchases were executed at prices ranging from $5.94 to $6 per share from Sept. 25 through Oct. 10 and now give Impactive an 8.6% interest in Avid Technology.
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.
Company on Track for Amphora NDA Resubmission to the U.S. FDA Phase 2b AMPREVENCE Trial Results Anticipated in Q4 2019 Management to Host Conference Call Thursday, November 7, 2019 at 11:00 a.m. EST SAN ...
-- Conference Call Scheduled for 11:00 a.m. EST -- SAN DIEGO , Oct. 24, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial ...
SAN DIEGO , Sept. 25, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, will present and host investor meetings at the upcoming 2019 Cantor Global ...
SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) ("Evofem" or the "Company") today announced the last patient has completed her last visit in AMPREVENCE, the Phase 2b clinical trial evaluating the Company's lead product candidate Amphora®, a Multipurpose Vaginal pH Regulator (MVP-R™), for the prevention of acquisition of chlamydia and gonorrhea in women (as primary and secondary endpoints, respectively).
SAN DIEGO , Aug. 22, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, is set to present at two healthcare equity conferences in early September. ...
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
Amphora NDA Resubmission Remains on Track for Q4 2019 Management to Host Conference Call Tuesday August 6, 2019 at 11:00 a.m. EDT SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: ...
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (EVFM) (Evofem), a clinical-stage biopharmaceutical company, today reported additional data from its Phase 3 'AMPOWER' clinical trial of Amphora® for the prevention of pregnancy. These findings reveal that the use of Amphora, a first-in-class investigational Multipurpose Vaginal pH Regulator (MVP-R™), may improve sexual satisfaction and have a positive impact on women's sex lives. The analysis also confirmed certain previously reported safety and efficacy data.
-- Conference Call Scheduled for 11:00 a.m. EDT -- SAN DIEGO , July 30, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business ...
SAN DIEGO, July 1, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (EVFM) (Evofem), a clinical-stage biopharmaceutical company was added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective at the U.S. market open on July 1, 2019, according to a final list of additions posted June 28. "The inclusion of Evofem Biosciences in the Russell 3000 Index is indicative of the company's significant progress and growth.
SAN DIEGO and INCLINE VILLAGE, Nev., June 10, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc. (PDLI) (PDL) today announced the closing of the second tranche for $50 million of an aggregate $80 million strategic financing from PDL and existing Evofem investors, Invesco Asset Management, LTD. (Invesco) and Woodford Investment Management (WIM). "This investment from PDL and the support from two long-time investors enables us to execute our commercialization strategy for Amphora® and to prepare for its anticipated launch as the first-in-class Multipurpose Vaginal pH Regulator for hormone-free birth control in the second quarter of 2020, assuming FDA approval," said Saundra Pelletier, CEO of Evofem Biosciences.